Galena Biopharma Inc (NASDAQ:GALE) Increases Net Revenue Estimates


Dallas, Texas 03/24/2014 (FINANCIALSTRENDS) – Galena Biopharma Inc (NASDAQ:GALE) reported its Q4 and 2013 year-end results recently. The company had a successful Abstral launch in the 2013 Q4 which resulted in $2.5M in net-revenue which was consistent with its guidance of $1.5 to $3M. Galena Biopharma Inc (NASDAQ:GALE) is raising its 2014 Abstral net-revenue estimates to $11-$15 million against its previous guidance of $8-$12 million. Its late stage pipeline-milestones in 2014 include completion of the NeuVax Phase III enrollment in breast -cancer under the SPA (special protocol assessment).

Also in the pipeline is completion of the Phase II enrollment for its GALE-301 in the treatment of ovarian cancer, &  initiating  the GALE-401 in orphan-disease essential thrombocythemia under 505B2 accelerated development-pathway. Galena Biopharma Inc (NASDAQ:GALE) recognizes revenue from  sale of Abstral to the wholesale pharma distributors, net-of-product-related discounts and allowances, product-returns, rebates and chargebacks, as well as patient-assistance benefits, as applicable. The net revenue was $1.3M in the Q4 of 2013 and $2.5M for the year that ended 31 December 2013.

The cost of revenue (with the exclusion of amortization of some acquired intangible assets) & the gross-profit were $0.3M & $1.0M for the Q4 of 2013 & were $0.5 million &  $2.0 million for the year that ended Dec31, 2013, respectively. The operating loss for the Q4 of 2013 was $12.4M, including $1.7M in stock-based compensation, and $33.8M, including $2.9M in stock-based-compensation charges, for the year that ended Dec 31, 2013, in comparison to $5.6 million, which included $0.7 million in stock-based-compensation, and $21.2M, including $1.9M in stock based compensation, for those same periods of 2012.

The rise in net operating loss y-o- is mainly the result of the company’s increased activity & enrollment in their Phase III PRESENT trial for the drug- NeuVax and a rise in selling &  marketing expenses that were associated with launch of the 1st  & only commercial-product, Abstral.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.